November was a pivotal month in gastroenterology, marked by the first-ever FDA-approved treatment for pediatric IBS-C, updated AGA guidelines pushing for early use of high-efficacy therapies in Crohn’s disease, and new safety data supporting that shift. Yet progress brought new pressure points: research highlighted worsening geographic disparities in GI access, and AI tools—despite hype—failed to meet clinical standards for IBS dietary guidance, reinforcing the continued need for human expertise in digestive care.
Keep Reading
Add A Comment